UNITED STATES (OBSERVATORY NEWS) — Chronic pain and inflammation are major factors in the development of a depressive disorder. To better understand the physiological processes that occur during depression, scientists are studying specific metabolic pathways associated with inflammation.
One of them is the kynurenine pathway, in which the tryptophan amino acid supplied with food is converted to nicotinic acid.
A group of Japanese scientists has shown that elevated blood levels of anthranilic acid, an important metabolite (intermediate) of the kynurenine pathway, can serve as a marker for identifying people who are at risk of developing major depressive disorder. An article about this study is published in the journal Scientific Reports.
“Various scientific evidence suggests that tryptophan metabolism plays an important role in the development of symptoms of depressive disorder,” says Yasuko Yamamoto, one of the authors of the article. Previously, many studies have shown that patients with depression and similar conditions have an increased level of various tryptophan metabolites in the blood. This led scientists to the idea that intermediate products of the kynurenine pathway can be used as biomarkers of a depressed state.
To test his hypothesis, Yamamoto and her colleagues analyzed blood samples from 61 patients, the results of clinical tests of which indicated a high risk of developing a major depressive disorder. As a control group, serum samples from 51 conditionally healthy individuals were used.
The level of various kynurenine pathway metabolites was measured by high performance liquid chromatography. In patients at risk, an increased concentration of anthranilic acid was detected in the blood serum compared with the control group. In addition, serum tryptophan levels were lower in women at increased risk of developing depression.
These results are consistent with previous data on increased activity of the kynurenine pathway in patients at risk of developing major depressive disorder. Similar results were obtained for patients with chronic pain.
It was also found that tryptophan metabolite profiles predict the development of depressive symptoms. Further study of samples of 33 patients who experienced regression to a more severe condition showed that an increase in serum anthranilic acid over time correlated with worsening clinical test results.
“This finding confirms that there is indeed a strong direct correlation between the levels of anthranilic acid in the blood and the severity of depression on the clinical depression scale,” summarizes the lead author of the article, Kuniaki Saito. “Monitoring the level of tryptophan metabolites can be useful for implementing proactive medications for depressive symptoms.”
This article is written and prepared by our foreign editors writing for OBSERVATORY NEWS from different countries around the world – material edited and published by OBSERVATORY staff in our newsroom.
Contact us: [email protected]
Support The OBSERVATORY from as little as $1 – it only takes a minute. Thank you.
We are OBSERVATORY — the only funding and support we get from people – we are categorically not funded by any political party, any government somewhere or from any grouping that supports certain interests – the only support that makes OBSERVATORY possible came from you.